Improvements in FEV1 and St George?s Respiratory Questionnaire (SGRQ) at 4 and 16 weeks on benralizumab are strongly associated with clinical remission at 1 year - Amsterdam 2025

Multifaceted evaluation of biologics in airway diseases: biomarkers, symptoms and beyond

Chair(s): Dina Visca, Antoine Beurnier

Session type: Poster session

Improvements in FEV1 and St George?s Respiratory Questionnaire (SGRQ) at 4 and 16 weeks on benralizumab are strongly associated with clinical remission at 1 year

Jennifer Logan

EVENTS HOME

Poster
Abstract

Previous presentation

Next presentation

Session content

Effect of tezepelumab on small airway dysfunction in real-life severe asthma

Toshihiro Shirai

Poster

Abstract

Multi-Tissue Molecular Differences Between Type 2 low Asthma and Healthy Individuals: Associations with CT Features

Nazanin Zounemat-kermani

Poster

Abstract

Role of Epithelial Barrier Integrity in Biologic Treatment Response of Severe Asthmatics With/Out Chronic Rhinosinusitis With Nasal Polyps (CRSwNP): Study design and preliminary results

Nikoleta Bizymi

Poster

Abstract

Longitudinal study of the impact of severe asthma biologic treatment on the body mass index (BMI)

Claudia Ajayi

Poster

Abstract

Ex-vivo three-dimensional model of T2-asthma: effects of the monoclonal antibody against interleukin-4 receptor ?

Martina Lo Casto

Poster

Abstract

Improvements in FEV1 and St Georges Respiratory Questionnaire (SGRQ) at 4 and 16 weeks on benralizumab are strongly associated with clinical remission at 1 year

Jennifer Logan

Poster

Abstract

Effect of benralizumab on the levels of bronchial epithelial-produced alarmins, collectins and mucosal-associated chemokine CCL28 in the blood of patients with severe eosinophilic asthma

Virginija Kalinauskaite-zukauske

Poster

Abstract

REIMAGINE: A prospective real-world evaluation of clinical remission in patients with severe asthma treated with mepolizumab in a timely manner

David Ramos Barbon

Poster

Abstract

Success of biologics in patients with co-morbid severe asthma and COPD do we need a more individualised definition of success?

Rachel Burton

Poster

Abstract

The impact of biologics on VOC profiles in severe asthma a preliminary analysis

Sofi Vassileva

Poster

Abstract

Does frequency matter to patients? Views on current and upcoming severe asthma biologics

Bethan Wright

Poster

Abstract

Depemokimab reduces exacerbations in severe asthma versus other biologics: A multilevel network meta-regression

Arnaud Bourdin

Poster

Abstract

Mepolizumab reduces markers of airway remodelling in bronchial biopsies from patients with severe eosinophilic asthma after 6 months of treatment

Isabella Drummond

Poster

Abstract

The impact of Tezepelumab therapy on perceived asthma triggers: a multicentre real-life study.

Francesca Montagnolo

Poster

Abstract

Effect of benralizumab on small airways and CT imaging in patients with severe eosinophilic asthma

Italo Giovanni Bonatto

Poster

Abstract

Diaphragmatic function in severe asthma patients treated with biologics: The BIO-US study

Andrea Alessia Nardo

Poster

Abstract

Asthma control and QoL among Canadian patients with severe eosinophilic asthma (SEA): 2-year real-world results

Erika Penz

Poster

Abstract

T-ROSS study: Baseline characteristics and comorbidity burden

Gabriel Niza Fresno

Poster

Abstract

Biologic treatment outcomes for severe asthma in Singapore

Cheryn Yu Wei Choo

Poster

Abstract

Dupilumab improves long-term asthma control in German patients with severe asthma: Real-word data

Andreas Renner

Abstract

CDN Connection Issue

The ERS Congress 2025, Amsterdam

#{title}